MA46744A - Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v - Google Patents

Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v

Info

Publication number
MA46744A
MA46744A MA046744A MA46744A MA46744A MA 46744 A MA46744 A MA 46744A MA 046744 A MA046744 A MA 046744A MA 46744 A MA46744 A MA 46744A MA 46744 A MA46744 A MA 46744A
Authority
MA
Morocco
Prior art keywords
azetidine
inhibitors
mono
compounds containing
integrin alpha
Prior art date
Application number
MA046744A
Other languages
English (en)
Inventor
Pratik Devasthale
Suresh Dhanusu
Lawrence R Marcin
Fang Moore
Manoranjan Panda
Susan Nicole Pieniazek
Kumaravel Selvakumar
Guohua Zhao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46744A publication Critical patent/MA46744A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046744A 2016-11-08 2017-11-07 Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v MA46744A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418859P 2016-11-08 2016-11-08

Publications (1)

Publication Number Publication Date
MA46744A true MA46744A (fr) 2019-09-18

Family

ID=60409434

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046744A MA46744A (fr) 2016-11-08 2017-11-07 Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v

Country Status (15)

Country Link
US (2) US11014922B2 (fr)
EP (1) EP3538526B1 (fr)
JP (1) JP7264810B2 (fr)
KR (1) KR102506324B1 (fr)
CN (1) CN110167934B (fr)
AR (1) AR110139A1 (fr)
AU (1) AU2017359025A1 (fr)
BR (1) BR112019009129A2 (fr)
CA (1) CA3042710A1 (fr)
EA (1) EA201991127A1 (fr)
IL (1) IL266470A (fr)
MA (1) MA46744A (fr)
MX (1) MX2019005306A (fr)
TW (1) TW201819378A (fr)
WO (1) WO2018089355A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (fr) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
JP2020504120A (ja) 2016-12-29 2020-02-06 セントルイス ユニバーシティ インテグリンアンタゴニスト
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
IL279717B2 (en) * 2018-06-27 2024-05-01 Pliant Therapeutics Inc Amino acid compounds with non-branched linkers and methods of use
EP3843728A4 (fr) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CA3114240C (fr) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Derives d'imidazopyridine utilises en tant qu'inhibiteurs de l'integrine alpha4beta7
CA3115820A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composes pour l'inhibition de l'integrine .alpha.4.beta.7
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
WO2020092375A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
CA3148613A1 (fr) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Composes derives de la phenylalanine et utilisation comme inhibiteurs del'integrine alpha-4 beta-7
WO2021175196A1 (fr) * 2020-03-06 2021-09-10 清药同创(北京)药物研发中心有限公司 Modulateur de l'intégrine pyrrolidine et son utilisation
CN115335365B (zh) * 2020-03-26 2024-06-18 詹森药业有限公司 氨基环丁烷作为单酰基甘油脂肪酶调节剂
TW202216715A (zh) 2020-07-07 2022-05-01 大陸商四川海思科製藥有限公司 降解btk激酶的化合物、製造方法及其應用
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
CN114057732A (zh) * 2020-07-29 2022-02-18 清药同创(北京)药物研发中心有限公司 一种吡咯烷类整合素调节剂及其用途
US20240208968A1 (en) * 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
TW202308637A (zh) * 2021-04-30 2023-03-01 美商普萊恩醫療公司 整合素抑制劑之擴大劑量方案
EP4385985A1 (fr) 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Dérivé hétérocyclique, et composition et utilisation pharmaceutique de celui-ci
WO2023192687A1 (fr) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. Modulateurs des canaux calciques de type t comprenant un noyau azaspiroheptane et leurs procédés d'utilisation
WO2023192675A1 (fr) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. Modulateurs des canaux calciques de type t comprenant un noyau d'azaspirononane et leurs procédés d'utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
WO1999026945A1 (fr) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE αvβ¿3?
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
WO2000009503A1 (fr) 1998-08-13 2000-02-24 Merck & Co., Inc. Antagonistes de recepteurs d'integrine
DE60035779T2 (de) * 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
CA2436130A1 (fr) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Indoles substitues et utilisation de ceux-ci comme antagonistes d'integrine
WO2006108040A1 (fr) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Indoles substitues et leur utilisation en tant qu'antagonistes de l'integrine
WO2007141473A1 (fr) 2006-06-09 2007-12-13 Astrazeneca Ab Dérivés de phénylalanine
WO2008125811A1 (fr) 2007-04-11 2008-10-23 Astrazeneca Ab DÉRIVÉS DE N-[HÉTÉROARYLCARBONYL]-S-THIÉNYL-L-ALANINE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE α5β1
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
RU2017132433A (ru) * 2015-02-19 2019-03-19 Сайфлуор Лайф Сайенсиз, Инк. Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
WO2016172496A1 (fr) * 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Inhibiteurs de lsd1 et leurs utilisations
DK3538525T3 (da) * 2016-11-08 2022-08-29 Bristol Myers Squibb Co 3-substituerede propionsyrer som alpha-v-integrinhæmmere
CA3042693A1 (fr) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Amides de pyrrole en tant qu'inhibiteurs d'integrine .alpha.v

Also Published As

Publication number Publication date
US11014922B2 (en) 2021-05-25
TW201819378A (zh) 2018-06-01
CA3042710A1 (fr) 2018-05-17
KR102506324B1 (ko) 2023-03-03
CN110167934B (zh) 2022-06-10
JP2019537605A (ja) 2019-12-26
WO2018089355A1 (fr) 2018-05-17
KR20190076032A (ko) 2019-07-01
MX2019005306A (es) 2019-08-12
BR112019009129A2 (pt) 2019-07-16
EA201991127A1 (ru) 2019-10-31
JP7264810B2 (ja) 2023-04-25
AU2017359025A1 (en) 2019-06-20
CN110167934A (zh) 2019-08-23
IL266470A (en) 2019-07-31
US20210246136A1 (en) 2021-08-12
US20190270741A1 (en) 2019-09-05
EP3538526A1 (fr) 2019-09-18
US11639353B2 (en) 2023-05-02
AR110139A1 (es) 2019-02-27
EP3538526B1 (fr) 2024-04-10

Similar Documents

Publication Publication Date Title
MA46744A (fr) Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA41901A (fr) Compositions contenant de l'ibrutinib
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
AR104642A1 (es) Compuestos carboximidamida derivados de bencimidazol e imidazopiridina
EA201790806A1 (ru) Иммунорегулирующие средства
MA52856A (fr) Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
SV2016005279A (es) Inhibidores de diacilglicerol aciltransferasa 2
MA49377A (fr) Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë
FR3031744B1 (fr) Compositions d'additifs thermoassociatifs dont l'association est controlee et compositions lubrifiantes les contenant